A changed life: the life experiences of patients with psoriasis receiving biological treatment

Summary Background Psoriasis has a large negative impact on quality of life and is associated with both depression and anxiety. The introduction of biologics has improved treatment outcomes, but the ways in which patients perceive these improvements are not well characterized. Objectives To investig...

Full description

Saved in:
Bibliographic Details
Published in:British journal of dermatology (1951) Vol. 183; no. 3; pp. 516 - 523
Main Authors: Trettin, B., Feldman, S.R., Andersen, F., Danbjørg, D.B., Agerskov, H.
Format: Journal Article
Language:English
Published: England Oxford University Press 01-09-2020
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Background Psoriasis has a large negative impact on quality of life and is associated with both depression and anxiety. The introduction of biologics has improved treatment outcomes, but the ways in which patients perceive these improvements are not well characterized. Objectives To investigate the everyday life experiences of patients with psoriasis receiving biological treatment in order to gain an understanding of their needs and to improve the quality of care. Methods A qualitative narrative methodology was utilized. In total 48 h of participant observations during consultations, and 15 semistructured interviews, were conducted with patients receiving biological treatment. Data were analysed according to Ricoeur's theory of interpretation. Results Receiving biological treatment was experienced as a turning point, with a significant impact on physical, psychological and emotional levels. However, psychological consequences, such as isolation and social withdrawal, seemed to be a part of the patient's identity; the negative perceptions of psoriasis left marks behind that affected the patient's self‐image. Perceived fear of discontinuation of the biological treatment resulted in insecurity, and patients were reluctant to initiate discussion about these concerns with healthcare professionals. Conclusions Providing assistance when patients enter the transition of receiving biological treatment may be important. Patients’ fear of biological treatment being discontinued is an ongoing issue that healthcare professionals could address. What's already known about this topic? Patients with psoriasis are marked by the disease physically, psychologically and emotionally. The introduction of biologics has improved treatment outcomes and health‐related quality of life. What does this study add? This is the first qualitative study to explore the everyday life experiences of patients with psoriasis receiving biological treatment. The personal transition from having psoriasis to having clear skin is a major physical change, but psychological issues caused by psoriasis remain. Fear of treatment discontinuation is an ongoing emotion; patients are reluctant to initiate discussion about these concerns with healthcare professionals. What are the clinical implications of this work? Entering the personal transition of receiving biological treatment may require assistance from healthcare professionals. A patient‐centred approach is significant in order to recognize the need for individualized care of the patient. Healthcare professionals should address patients’ fear of discontinuation in order to reduce uncertainty and to ensure that patients are fully informed about their future treatment. Plain language summary available online
Bibliography:Funding sources
www.DrScore.com
Plain language summary
available online
Conflicts of interest
and founder and part owner of Causa Research, a company dedicated to enhancing patients’ adherence to treatment. F.A., D.B.D. and H.A. have no conflicts of interest to declare
.
University of Southern Denmark, Odense University Hospital, Robert Wehnerts and Kirsten Wehnerts Fond, and Novartis
This study had some funding from industry (4 months of B.T.'s salary), but the funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript. S.R.F. received research, speaking and/or consulting support from Galderma, GSK/Stiefel, Almirall, Alvotech, LEO Pharma, BMS, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Ortho Dermatology, AbbVie, Samsung, Janssen, Lilly, Menlo, Merck, Novartis, Regeneron, Sanofi, Novan, Qurient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate and the National Psoriasis Foundation. He is founder and majority owner of
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0007-0963
1365-2133
DOI:10.1111/bjd.18876